Survodutide is an investigational clinical program.
Each answer stays attached to the compound identity and destination records. This is a verification guide, not medical or legal advice, a seller recommendation, or proof of availability.
Survodutide is an investigational clinical program. No seller listing in New Zealand can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Resolve the exact identity of Survodutide through SYNCHRONIZE-1 Phase 3 study - NCT06066515 from ClinicalTrials.gov. Then search Unapproved peptide products health warning from New Zealand Medicines and Medical Devices Safety Authority for the destination product record and Product and application search from New Zealand Medicines and Medical Devices Safety Authority for the seller, establishment, or supply route in New Zealand. A match in one record does not replace the other two checks.
No. A page using the name Survodutide, local currency, a domestic delivery claim, or a familiar package image is only a lead. This is an investigational program, not an approved product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, or regulatory status. For New Zealand, the exact product, presentation, seller identity, current record status, and claimed supply route must resolve through the official sources on this page.
9 study records currently list 34 locations in this country, including 8 locations individually marked Recruiting.
Registry update: 24 July 2026Survodutide is an investigational clinical program. No seller listing in New Zealand can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity source: SYNCHRONIZE-1 Phase 3 study - NCT06066515 / ClinicalTrials.gov ↗A credible result must keep these separate. The official links answer different questions and should be checked in sequence.
SYNCHRONIZE-1 Phase 3 study - NCT06066515 is maintained by ClinicalTrials.gov. Open the current record and match the exact name, holder, presentation, legal entity, status, or route relevant to the claim.
Open SYNCHRONIZE-1 Phase 3 study - NCT06066515 ↗Unapproved peptide products health warning is maintained by New Zealand Medicines and Medical Devices Safety Authority. Open the current record and match the exact name, holder, presentation, legal entity, status, or route relevant to the claim.
Open Unapproved peptide products health warning ↗Product and application search is maintained by New Zealand Medicines and Medical Devices Safety Authority. Open the current record and match the exact name, holder, presentation, legal entity, status, or route relevant to the claim.
Open Product and application search ↗New Zealand now has a peptide-specific Medsafe advisory that directly addresses online claims, unapproved products, research-purpose labels, and retatrutide. That warning must be checked before any product, seller, import, or price comparison.
The country guide supplies the local verification sequence. It does not convert an online listing into an authorized product or verified seller.
Start with Medsafe's 21 May 2026 consumer advisory because it addresses unapproved peptide products, online promotion, research-purpose wording, and retatrutide specifically.
Use Medsafe's Product/Application Search to determine whether the exact product has consent to be marketed in New Zealand; a similar ingredient name is not a matching product record.
Use the Pharmacy Licence Register to match the legal entity, trading name, premises, and region. A product search does not verify the seller, and a pharmacy record does not approve every offer.
Open the live record and confirm its current status. A linked source begins the verification process; it does not mean Peptide Local authenticated a product or seller.